Here’s Why Wednesday Is The Next Big Catalyst For Puma Biotech

Puma Biotechnology Inc PBYI 9.89% shares skyrocketed 39.1 percent in Monday’s trading session after the FDA’s review of breast cancer drug candidate neratinib released on Monday was relatively benign. However, even after the big Monday move, JPMorgan said the options market is pricing in 60 percent implied volatility in the stock this week ahead of neratinib’s approval vote on Wednesday.

FDA’s Concerns: Side Effects, Design Changes

The FDA raised concerns about neratinib’s diarrhea risk and changes made to the pivotal clinical trial.

“The tolerability of neratinib in this patient population is a concern given the frequent dose interruptions, reductions and discontinuations observed, mostly due to diarrhea,” the FDA wrote.

While the criticisms are certainly not good news, Puma investors were well aware of these particular concerns prior to the FDA’s review. Nearly 40 percent of the patients treated with neratinib reportedly experienced at least grade-3 diarrhea.

The study design changes will likely be central to the decision of whether or not to approve neratinib. In March 2016, the FDA recommended Puma delay its approval application for neratinib due to the design changes, but the company went ahead with the application anyway.

Upcoming FDA Panel

FDA Oncology Center director Richard Pazdur has allotted just five hours for the neratinib advisory committee meeting. Such a relatively short session could be bad news for Puma. Pazdur had scheduled half-hour sessions in the past to shoot down flawed cancer drugs.

It’s easy to see how rejection of neratinib could generate 60-percent downside for Puma. However, with the stock’s current 33.1 short percent of float, an approval could easily send…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common SenseI don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!